Literature DB >> 20654182

[Current state of diagnosis and treatment of allergic rhinitis in China].

Luo Zhang1, Jun-min Wei, De-min Han.   

Abstract

OBJECTIVE: To investigate the understanding among otolaryngologists and perspectives on the diagnosis and management of allergic rhinitis in major cities in China.
METHODS: A survey among otolaryngologists in mainland China was carried out through questionnaire, including the medical history, diagnosis and pharmacotherapy.
RESULTS: The survey was conducted in 508 otolaryngologists. In general otolaryngology head and neck surgery clinic, the patients with allergic rhinitis was about 19% +/- 14%, which was of 35% +/- 17% in rhinological clinic. Most of the otolaryngologists (61% +/- 29%) diagnosed AR based on medical history and nasal examination. Only 35% +/- 28% of the otolaryngologists used skin prick test or specific IgE serum test. 70% +/- 27% of the patients with AR were offered nasal steroids, 49% +/- 32% and 36% +/- 28% of the patients were offered oral or nasal antihistamines respectively. Only 24% +/- 17% of patients realized the importance of follow-up.
CONCLUSIONS: Allergic rhinitis is a core component in the specialty of otolaryngology head and neck surgery. The diagnosis and management of allergic rhinitis is sub-optimal. Chinese otolaryngologists need continuous education in aspects of diagnosis and management of allergic rhinitis.

Entities:  

Mesh:

Year:  2010        PMID: 20654182

Source DB:  PubMed          Journal:  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1673-0860


  2 in total

1.  Prevalence of allergic rhinitis among adults in urban and rural areas of china: a population-based cross-sectional survey.

Authors:  Ming Zheng; Xiangdong Wang; Mingyu Bo; Kuiji Wang; Yan Zhao; Fei He; Feifei Cao; Luo Zhang; Claus Bachert
Journal:  Allergy Asthma Immunol Res       Date:  2014-11-25       Impact factor: 5.764

Review 2.  Prevalence of allergic rhinitis in china.

Authors:  Yuan Zhang; Luo Zhang
Journal:  Allergy Asthma Immunol Res       Date:  2013-12-12       Impact factor: 5.764

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.